Pharmacist Support in Management of HR+/HER2- Breast Cancer

EP: 1.Disease Factors Influencing Treatment Pathways For HR+/HER2- Advanced Breast Cancer

EP: 2.Successful Clinical Outcomes With Treatment in Advanced-Stage Breast Cancer

EP: 3.The Impact of Pharmacists in Treatment Pathways of HR+/HER2- Breast Cancer

EP: 4.Impact of SERD/SERM Development in Treatment Landscape for Breast Cancer

EP: 5.Treatment Options in Patients With PIK3CA Mutation

EP: 6.Utilizing Multidisciplinary and Patient-Centered Care to Manage Drug Toxicity

EP: 7.Emerging Treatment Pathways For Management of HR+/HER2- Breast Cancer

EP: 8.Pharmacist-Driven Treatment Options for Patients With HR+/HER2- Breast Cancer

EP: 9.Addressing Disparities in Clinical Trial Settings

EP: 10.Target Outcomes in HR+/HER2- Treatment Management

EP: 11.Emphasizing Electronic Medical Records in Toxicity Management

EP: 12.Anticipated Updates in HR+/HER2- Treatment Options

EP: 13.Optimizing Current Therapies and Maintaining Quality of Life in HR+/HER2- Breast Cancer Treatment

EP: 14.Factors Guiding Treatment of HR+/HER2- Breast Cancer

EP: 15.Evolution of Pharmacist Role in Treatment and Management of Breast Cancer

EP: 16.Pharmacist Involvement in Treatment Management for Breast Cancer

EP: 17.Current Treatment Landscape for HR+/HER2- Breast Cancer

EP: 18.Toxicity Management in Breast Cancer Treatment

Now Viewing

EP: 19.Pharmacist Support in Management of HR+/HER2- Breast Cancer

EP: 20.Evaluating Evidence in HR+/HER2- Breast Cancer Treatment Landscape

EP: 21.Comparing HR+/HER2- Breast Cancer in Academic and Community Health Settings

EP: 22.Anticipated Developments on the Horizon for Patients With HR+/HER2- Breast Cancer

EP: 23.Trajectory of HR+/HER2- Breast Cancer Treatment

Alisa Vinokurov, PharmD: The role of the pharmacist in clinical practice for the management of HR [hormone receptor]-positive, HER2-negative breast cancer is pretty holistic. We handle the supportive care. We do all of the premedications that need to be sent off to the pharmacy. We give them an encompassing patient education. Then for the drug interactions, when physicians have any questions, we’re there to double-check. We’re there to verify that it’s OK to give.

[As far as] contraindications, as Dr McHayleh likes to say, we’re the label experts. We’re there to know the contraindications that may occur with these drugs that are being prescribed. In special populations, we don’t have a very wide range. It’s mostly women, and they’re typically healthy. Some of them may not be, but most of the time they’re very healthy. When they need adjustments, we’re there to make any dosing adjustments. [As far as] treatment adherence, that’s a great service to provide as a pharmacist, to make sure at their checkups that they’re taking their medications correctly. If there’s a day that they skipped, we inform them about the proper instructions [regarding] what happens if you skip a day, and the number of hours between when you last administered your drug to when you can take the next one. We can educate them on that and be there to support them.

Because this is such a new field for a pharmacist to be niched and very involved in, some advice for a clinical pharmacist would be to push the boundaries. You’re there to provide medication management. You’re there to practice as a clinician, as Dr McHayleh likes to call us. We’re there, we know the treatments, the adverse effects, and the dose adjustments. So we need to show our value and show that we can be a clinician practicing alongside these oncologists and benefit the patients in a way that we previously weren’t able to without a pharmacist. We focus on the dosing and the toxicity. Because the oncologists are very busy and see so many patients, things like that sometimes get missed. Having a pharmacist there every day, all day, [tracking] these patients and following up on them is something this field really needs. That would be advisable for a lot of practices in the oncology field.

Transcript edited for clarity.